Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis

Autores
de Moreno, Maria Alejandra; del Carmen, Silvina Andrea; Chatel, Jean Marc; Azevedo, Vasco; Langella, Philippe; Bermudez Humaran, Luis; Leblanc, Jean Guy Joseph
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Inflammatory bowel diseases (IBDs) affect the gastrointestinal tract and are characterized by recurrent inflammation that requires lifelong therapies. Probiotics such as lactic acid bacteria (LAB) have been proposed to complement current treatment protocols for these patients; however, their characteristics are strain dependent. In this regard, certain novel characteristics are only possible through the genetic modification of these beneficial micro-organisms. Different delivery systems, such as protein delivery of anti-oxidant enzymes and anti-inflammatory cytokines, have been shown to be effective in preventing and treating IBD in animal models. In this study, the safety of the recombinant LAB (recLAB) Streptococcus thermophilus CRL807: CAT, S. thermophilus CRL807: SOD, Lactococcus lactis NCDO2118 pXILCYT: IL-10, L. lactis MG1363 pValac: IL-10 and L. lactis MG1363 pGroESL: IL-10 with proven beneficial effects was compared to their progenitor strains S. thermophilus CRL807, L. lactis NCDO2118 or L. lactis MG1363. The prolonged administration of these genetically modified strains showed that they were just as safe as the native strains from which they derive, as demonstrated by normal animal growth and relative organ weights, absence of microbial translocation from the gastrointestinal tract, normal blood parameters and intestinal histology. The results show the potential use of these recLAB in future therapeutic formulations; however, the use of modern bio-containment systems is required for the future acceptance of these recLAB by the medical community and patients with IBD.
Fil: de Moreno, Maria Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
Fil: del Carmen, Silvina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
Fil: Chatel, Jean Marc. INRA and AgroParisTech; Francia
Fil: Azevedo, Vasco. Universidade Federal do Minas Gerais; Brasil
Fil: Langella, Philippe. INRA and AgroParisTech; Francia
Fil: Bermudez Humaran, Luis. INRA and AgroParisTech; Francia
Fil: Leblanc, Jean Guy Joseph. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
Materia
Lactic Acid Bacteria
Genetically Modified Microorganisms
Safety
Colitis
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/39253
Acceder
id CONICETDig_a6e8656b15f28f8fe7a7c185c6457685
oai_identifier_str oai:ri.conicet.gov.ar:11336/39253
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitisde Moreno, Maria Alejandradel Carmen, Silvina AndreaChatel, Jean MarcAzevedo, VascoLangella, PhilippeBermudez Humaran, LuisLeblanc, Jean Guy JosephLactic Acid BacteriaGenetically Modified MicroorganismsSafetyColitisInflammatory bowel diseases (IBDs) affect the gastrointestinal tract and are characterized by recurrent inflammation that requires lifelong therapies. Probiotics such as lactic acid bacteria (LAB) have been proposed to complement current treatment protocols for these patients; however, their characteristics are strain dependent. In this regard, certain novel characteristics are only possible through the genetic modification of these beneficial micro-organisms. Different delivery systems, such as protein delivery of anti-oxidant enzymes and anti-inflammatory cytokines, have been shown to be effective in preventing and treating IBD in animal models. In this study, the safety of the recombinant LAB (recLAB) Streptococcus thermophilus CRL807: CAT, S. thermophilus CRL807: SOD, Lactococcus lactis NCDO2118 pXILCYT: IL-10, L. lactis MG1363 pValac: IL-10 and L. lactis MG1363 pGroESL: IL-10 with proven beneficial effects was compared to their progenitor strains S. thermophilus CRL807, L. lactis NCDO2118 or L. lactis MG1363. The prolonged administration of these genetically modified strains showed that they were just as safe as the native strains from which they derive, as demonstrated by normal animal growth and relative organ weights, absence of microbial translocation from the gastrointestinal tract, normal blood parameters and intestinal histology. The results show the potential use of these recLAB in future therapeutic formulations; however, the use of modern bio-containment systems is required for the future acceptance of these recLAB by the medical community and patients with IBD.Fil: de Moreno, Maria Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; ArgentinaFil: del Carmen, Silvina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; ArgentinaFil: Chatel, Jean Marc. INRA and AgroParisTech; FranciaFil: Azevedo, Vasco. Universidade Federal do Minas Gerais; BrasilFil: Langella, Philippe. INRA and AgroParisTech; FranciaFil: Bermudez Humaran, Luis. INRA and AgroParisTech; FranciaFil: Leblanc, Jean Guy Joseph. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; ArgentinaSociety for General Microbiology2016-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/39253de Moreno, Maria Alejandra; del Carmen, Silvina Andrea; Chatel, Jean Marc; Azevedo, Vasco; Langella, Philippe; et al.; Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis; Society for General Microbiology; Journal Of Medical Microbiology; 65; 9; 9-2016; 1038-10460022-26151473-5644CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1099/jmm.0.000323info:eu-repo/semantics/altIdentifier/url/http://jmm.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.000323info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:43:06Zoai:ri.conicet.gov.ar:11336/39253instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:43:06.924CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis
title Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis
spellingShingle Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis
de Moreno, Maria Alejandra
Lactic Acid Bacteria
Genetically Modified Microorganisms
Safety
Colitis
title_short Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis
title_full Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis
title_fullStr Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis
title_full_unstemmed Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis
title_sort Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis
dc.creator.none.fl_str_mv de Moreno, Maria Alejandra
del Carmen, Silvina Andrea
Chatel, Jean Marc
Azevedo, Vasco
Langella, Philippe
Bermudez Humaran, Luis
Leblanc, Jean Guy Joseph
author de Moreno, Maria Alejandra
author_facet de Moreno, Maria Alejandra
del Carmen, Silvina Andrea
Chatel, Jean Marc
Azevedo, Vasco
Langella, Philippe
Bermudez Humaran, Luis
Leblanc, Jean Guy Joseph
author_role author
author2 del Carmen, Silvina Andrea
Chatel, Jean Marc
Azevedo, Vasco
Langella, Philippe
Bermudez Humaran, Luis
Leblanc, Jean Guy Joseph
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Lactic Acid Bacteria
Genetically Modified Microorganisms
Safety
Colitis
topic Lactic Acid Bacteria
Genetically Modified Microorganisms
Safety
Colitis
dc.description.none.fl_txt_mv Inflammatory bowel diseases (IBDs) affect the gastrointestinal tract and are characterized by recurrent inflammation that requires lifelong therapies. Probiotics such as lactic acid bacteria (LAB) have been proposed to complement current treatment protocols for these patients; however, their characteristics are strain dependent. In this regard, certain novel characteristics are only possible through the genetic modification of these beneficial micro-organisms. Different delivery systems, such as protein delivery of anti-oxidant enzymes and anti-inflammatory cytokines, have been shown to be effective in preventing and treating IBD in animal models. In this study, the safety of the recombinant LAB (recLAB) Streptococcus thermophilus CRL807: CAT, S. thermophilus CRL807: SOD, Lactococcus lactis NCDO2118 pXILCYT: IL-10, L. lactis MG1363 pValac: IL-10 and L. lactis MG1363 pGroESL: IL-10 with proven beneficial effects was compared to their progenitor strains S. thermophilus CRL807, L. lactis NCDO2118 or L. lactis MG1363. The prolonged administration of these genetically modified strains showed that they were just as safe as the native strains from which they derive, as demonstrated by normal animal growth and relative organ weights, absence of microbial translocation from the gastrointestinal tract, normal blood parameters and intestinal histology. The results show the potential use of these recLAB in future therapeutic formulations; however, the use of modern bio-containment systems is required for the future acceptance of these recLAB by the medical community and patients with IBD.
Fil: de Moreno, Maria Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
Fil: del Carmen, Silvina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
Fil: Chatel, Jean Marc. INRA and AgroParisTech; Francia
Fil: Azevedo, Vasco. Universidade Federal do Minas Gerais; Brasil
Fil: Langella, Philippe. INRA and AgroParisTech; Francia
Fil: Bermudez Humaran, Luis. INRA and AgroParisTech; Francia
Fil: Leblanc, Jean Guy Joseph. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucuman. Centro de Referencia Para Lactobacilos; Argentina
description Inflammatory bowel diseases (IBDs) affect the gastrointestinal tract and are characterized by recurrent inflammation that requires lifelong therapies. Probiotics such as lactic acid bacteria (LAB) have been proposed to complement current treatment protocols for these patients; however, their characteristics are strain dependent. In this regard, certain novel characteristics are only possible through the genetic modification of these beneficial micro-organisms. Different delivery systems, such as protein delivery of anti-oxidant enzymes and anti-inflammatory cytokines, have been shown to be effective in preventing and treating IBD in animal models. In this study, the safety of the recombinant LAB (recLAB) Streptococcus thermophilus CRL807: CAT, S. thermophilus CRL807: SOD, Lactococcus lactis NCDO2118 pXILCYT: IL-10, L. lactis MG1363 pValac: IL-10 and L. lactis MG1363 pGroESL: IL-10 with proven beneficial effects was compared to their progenitor strains S. thermophilus CRL807, L. lactis NCDO2118 or L. lactis MG1363. The prolonged administration of these genetically modified strains showed that they were just as safe as the native strains from which they derive, as demonstrated by normal animal growth and relative organ weights, absence of microbial translocation from the gastrointestinal tract, normal blood parameters and intestinal histology. The results show the potential use of these recLAB in future therapeutic formulations; however, the use of modern bio-containment systems is required for the future acceptance of these recLAB by the medical community and patients with IBD.
publishDate 2016
dc.date.none.fl_str_mv 2016-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/39253
de Moreno, Maria Alejandra; del Carmen, Silvina Andrea; Chatel, Jean Marc; Azevedo, Vasco; Langella, Philippe; et al.; Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis; Society for General Microbiology; Journal Of Medical Microbiology; 65; 9; 9-2016; 1038-1046
0022-2615
1473-5644
CONICET Digital
CONICET
url http://hdl.handle.net/11336/39253
identifier_str_mv de Moreno, Maria Alejandra; del Carmen, Silvina Andrea; Chatel, Jean Marc; Azevedo, Vasco; Langella, Philippe; et al.; Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis; Society for General Microbiology; Journal Of Medical Microbiology; 65; 9; 9-2016; 1038-1046
0022-2615
1473-5644
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1099/jmm.0.000323
info:eu-repo/semantics/altIdentifier/url/http://jmm.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.000323
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Society for General Microbiology
publisher.none.fl_str_mv Society for General Microbiology
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613356519948288
score 13.070432

Publicaciones similares